Will the Kimberly-Clark/Kenvue merger close by December 31, 2026?

Deal announced 11/2/2025 with expected close H2 2026 — 9-13 months is standard for large consumer goods mergers. Shareholder approval complete (96-99%). JPMorgan financing committed. K-C IFP sale provides financing proceeds. Primary risk is FTC review timeline — if FTC issues a second request, that adds 6+ months, which could push closing into Q1 2027. However, the limited category overlap between K-C (paper/tissue) and KVUE (OTC health) should facilitate faster regulatory clearance than a same-category merger. Tylenol litigation is unlikely to trigger MAC clause given K-C explicitly evaluated this risk.

The base rate for announced large mergers with shareholder approval to close within the stated timeline is approximately 70-80%. K-C/KVUE has favorable characteristics: overwhelming shareholder support, committed financing, limited antitrust concerns. Deductions from the base rate: (1) FTC second request possibility adds timeline risk (~15% probability of meaningful delay), (2) Tylenol litigation could create MAC clause uncertainty (~5% probability of deal disruption), (3) K-C IFP sale must close on schedule for financing (~5% probability of complication). Net probability: ~68%.

All major deal milestones are achieved except regulatory clearance. The deal's H2 2026 target gives it a 6-10 month window from today (March 2026). If FTC clears without conditions or with minor divestitures (which the analysis suggests is the most likely outcome), the deal closes on schedule. Even a second request, which typically adds 4-6 months of additional review, could still allow closing by December 2026 if issued soon. The deal would need an outright FTC challenge or a major unexpected development (financing collapse, MAC clause) to miss the H2 2026 window.

High-probability deal completion scenario. All controllable factors are done (shareholder approval, financing). FTC review of a complementary consumer products merger typically takes 3-6 months without a second request. If filed in early 2026 and HSR clock has been running, clearance could come Q2-Q3 2026. The IFP sale and limited overlap reduce second request probability. I estimate 73% probability the deal closes by December 31, 2026.

Large consumer products mergers have a strong track record of closing. The K-C/KVUE deal has all the hallmarks of a closing-destined merger: overwhelming shareholder support, committed financing, strategic logic, and limited horizontal overlap. The 30% probability of not closing by year-end reflects: FTC delay risk (~15%), broader regulatory uncertainty (~5%), litigation-related complications (~5%), and tail risk events like financing withdrawal or macro disruption (~5%).

I'm slightly more cautious than base rates suggest. The current FTC has shown willingness to extend review timelines even for deals it ultimately clears. A second request scenario, even if it results in unconditional clearance, could add enough time to push closing to Q1 2027. Additionally, K-C's IFP sale must close successfully for the financing plan to work — that's a dependency that introduces slight execution risk. 67% probability the deal closes by December 31, 2026.

Shareholder approval complete, financing committed, limited antitrust overlap. High probability of closing within the H2 2026 timeline. FTC review is the only meaningful hurdle, and complementary nature of the deal reduces regulatory risk. 75% probability.

Base rate for announced large mergers with full shareholder approval closing within 13 months is ~75%. Slight deduction for current FTC stance and Tylenol litigation tail risk. 70% probability of closing by December 31, 2026.

Strong deal fundamentals with one primary risk (FTC timeline). Even with a second request, the deal could close by December 2026 if the review concludes by Q4. Limited overlap between paper products and OTC health supports efficient review. 72% probability.